Abstract
3-(4-Geranyloxy-3-methoxyphenyl)-2-trans propenoic acid is a secondary metabolite biosynthetically related to ferulic acid in which a geranyl chain is attached to the phenolic group, extracted from Acronychia baueri Schott (Fam. Rutaceae). In the last five years some of the pharmacological properties of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid and its semisynthetic derivatives began to be characterized. In particular the ethyl ester showed a series of interesting biological effects such colon and tongue cancers chemoprevention by dietary feeding in rats and other effects closely related to cancer growth and development. Then 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid becomes a novel candidate as chemopreventive drug for the cure of various types of cancer and synthesis of some novel derivatives of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid, other than esters, has been recently reported. The aim of this review is to examine in detail the properties of the title compound so far reported in the literature from a chemical and pharmacological point of view.
Keywords: Acronychia baueri, Anticancer activity, Ferulic acid derivatives, 3-(4'-Geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid, Rutaceae
Anti-Cancer Agents in Medicinal Chemistry
Title: 3-(4-Geranyloxy-3-Methoxyphenyl)-2-trans Propenoic Acid: A Novel Promising Cancer Chemopreventive Agent
Volume: 6 Issue: 6
Author(s): Massimo Curini, Francesco Epifano, Salvatore Genovese, Maria Carla Marcotullio and Luigi Menghini
Affiliation:
Keywords: Acronychia baueri, Anticancer activity, Ferulic acid derivatives, 3-(4'-Geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid, Rutaceae
Abstract: 3-(4-Geranyloxy-3-methoxyphenyl)-2-trans propenoic acid is a secondary metabolite biosynthetically related to ferulic acid in which a geranyl chain is attached to the phenolic group, extracted from Acronychia baueri Schott (Fam. Rutaceae). In the last five years some of the pharmacological properties of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid and its semisynthetic derivatives began to be characterized. In particular the ethyl ester showed a series of interesting biological effects such colon and tongue cancers chemoprevention by dietary feeding in rats and other effects closely related to cancer growth and development. Then 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid becomes a novel candidate as chemopreventive drug for the cure of various types of cancer and synthesis of some novel derivatives of 3-(4-geranyloxy-3-methoxyphenyl)-2-trans propenoic acid, other than esters, has been recently reported. The aim of this review is to examine in detail the properties of the title compound so far reported in the literature from a chemical and pharmacological point of view.
Export Options
About this article
Cite this article as:
Curini Massimo, Epifano Francesco, Genovese Salvatore, Carla Marcotullio Maria and Menghini Luigi, 3-(4-Geranyloxy-3-Methoxyphenyl)-2-trans Propenoic Acid: A Novel Promising Cancer Chemopreventive Agent, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/187152006778699149
DOI https://dx.doi.org/10.2174/187152006778699149 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets
Current Signal Transduction Therapy Functional and Molecular Ultrasound Imaging: Concepts and Contrast Agents
Current Medicinal Chemistry Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Current Pharmaceutical Design Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis
Current Enzyme Inhibition Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry Extracellular Targeting of Synthetic Therapeutic Nucleic Acid Formulations
Current Gene Therapy Pleiotropic Role of HSF1 in Neoplastic Transformation
Current Cancer Drug Targets Autotaxin and Lysophosphatidic Acid Receptors as Novel Targets for the Radiosensitization of Tumor Vasculature in Non-Small Cell Lung Cancer
Current Angiogenesis (Discontinued) Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Current Signal Transduction Therapy From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Cetuximab Immunoliposomes Enhance Delivery of 5-FU to Skin Squamous Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry 3-MA Enhanced Chemosensitivity in Cisplatin Resistant Hypopharyngeal Squamous Carcinoma Cells via Inhibiting Beclin -1 Mediated Autophagy
Current Pharmaceutical Design Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy
Current Drug Targets Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Immune Modulation by Ionizing Radiation and its Implications for Cancer Immunotherapy
Current Pharmaceutical Design